CN115957258A - Wound healing lotion and preparation process and application thereof - Google Patents
Wound healing lotion and preparation process and application thereof Download PDFInfo
- Publication number
- CN115957258A CN115957258A CN202211554965.6A CN202211554965A CN115957258A CN 115957258 A CN115957258 A CN 115957258A CN 202211554965 A CN202211554965 A CN 202211554965A CN 115957258 A CN115957258 A CN 115957258A
- Authority
- CN
- China
- Prior art keywords
- parts
- wound healing
- lotion
- solution
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000006210 lotion Substances 0.000 title claims abstract description 70
- 230000029663 wound healing Effects 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229910021538 borax Inorganic materials 0.000 claims abstract description 32
- 239000004328 sodium tetraborate Substances 0.000 claims abstract description 32
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 32
- 235000008282 Sanguisorba officinalis Nutrition 0.000 claims abstract description 27
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract description 26
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 26
- 235000006533 astragalus Nutrition 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 206010052428 Wound Diseases 0.000 claims abstract description 22
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 235000008291 Poterium sanguisorba Nutrition 0.000 claims abstract description 19
- 241001061264 Astragalus Species 0.000 claims abstract description 18
- 210000004233 talus Anatomy 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 240000003705 Senecio vulgaris Species 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 240000004064 Poterium sanguisorba Species 0.000 claims abstract 7
- 239000000243 solution Substances 0.000 claims description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 14
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000012085 test solution Substances 0.000 claims description 12
- 241000147041 Guaiacum officinale Species 0.000 claims description 11
- 229940091561 guaiac Drugs 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 11
- 238000001704 evaporation Methods 0.000 claims description 10
- 238000004809 thin layer chromatography Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 239000000523 sample Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000012488 sample solution Substances 0.000 claims description 6
- 238000003892 spreading Methods 0.000 claims description 6
- 230000007480 spreading Effects 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000005507 spraying Methods 0.000 claims description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 claims description 3
- -1 hydrochloric acid saturated diethyl ether Chemical class 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- ROAYSRAUMPWBQX-UHFFFAOYSA-N ethanol;sulfuric acid Chemical compound CCO.OS(O)(=O)=O ROAYSRAUMPWBQX-UHFFFAOYSA-N 0.000 claims description 2
- 238000000643 oven drying Methods 0.000 claims description 2
- LUMVCLJFHCTMCV-UHFFFAOYSA-M potassium;hydroxide;hydrate Chemical compound O.[OH-].[K+] LUMVCLJFHCTMCV-UHFFFAOYSA-M 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 241000045403 Astragalus propinquus Species 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 19
- 239000013642 negative control Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000010298 pulverizing process Methods 0.000 description 5
- 239000012088 reference solution Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 description 3
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 229960001701 chloroform Drugs 0.000 description 3
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 description 3
- 238000001804 debridement Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 150000007965 phenolic acids Chemical class 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000013095 identification testing Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241000581682 Sanguisorba Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/90—Plate chromatography, e.g. thin layer or paper chromatography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a wound healing lotion and a preparation process and application thereof, wherein the wound healing lotion is mainly prepared from the following raw materials in parts by weight: 13-19 parts of salvia miltiorrhiza, 13-19 parts of groundsel, 8-14 parts of astragalus, 8-14 parts of garden burnet, 1-2 parts of borax and 4-8 parts of glycerol. According to the invention, an important composition formula is formed by taking salvia miltiorrhiza, astragalus membranaceus, garden burnet, groundsel, borax and glycerol as raw materials according to a reasonable proportion, and the wound healing lotion can be prepared after the formula is adopted for extraction, so that the healing of a wound surface which is difficult to heal can be promoted; the wound healing lotion has simple components, simple preparation method, low cost and convenient use, can be directly smeared on a wound surface, not only has the function of promoting wound healing, but also has the functions of bacteriostasis and anti-inflammation, exerts the integral regulation advantage of the traditional Chinese medicine compound, and is safe and has no toxic or side effect.
Description
Technical Field
The invention belongs to the technical field of wound healing lotion, and particularly relates to wound healing lotion as well as a preparation process and application thereof.
Background
Early debridement and irrigation treatments of difficult-to-heal wounds have become a consensus among experts in trauma surgery and health care. Research shows that the early flushing debridement of the polluted wound surface is carried out within 30 minutes after the wound is injured, pathogenic microorganisms polluted by the wound surface can be effectively removed, and the risk of infection is reduced. The wound surface is aseptically bandaged after being washed and debrided, and the infection can be avoided within 72 hours.
Some novel external preparations, such as anti-infective drugs, growth factors, novel dressings and antioxidants, are developed to control open wound infection and promote wound healing, but have the defects of single action link, easy granulation overgrowth, easy generation of drug resistance, high price and the like. Therefore, it is necessary to provide a wound healing lotion which can be used for early debridement and flushing of difficult-to-heal wounds to reduce infection, can be used for resisting infection and promoting growth during wound repair, preventing infection caused by colonization of multiple drug-resistant bacteria (MDRO), and can be used for war wound healing treatment with multi-stage effect to solve the problems.
The anal fistula healing lotion reported in the literature can be used for cleaning the wound surface of the anal fistula with the Crohn disease, controlling inflammation and promoting wound healing. However, the raw materials contain more flavonoid and phenolic acid components, and the solubility of the flavonoid and phenolic acid components is low, so that the stability of the washing liquid is poor.
Disclosure of Invention
The purpose of the invention is as follows: in order to solve the problems in the prior art, the invention provides a wound healing lotion and a preparation process and application thereof.
The technical scheme is as follows: in order to achieve the purpose, the invention adopts the following technical scheme:
the wound healing lotion is mainly prepared from the following raw materials in parts by weight:
13-19 parts of salvia miltiorrhiza, 13-19 parts of groundsel, 8-14 parts of astragalus, 8-14 parts of garden burnet, 1-2 parts of borax and 4-8 parts of glycerol.
Preferably, the wound healing lotion is mainly prepared from the following raw materials in parts by weight:
13-17 parts of salvia miltiorrhiza, 13-17 parts of groundsel, 8-12 parts of astragalus, 8-12 parts of garden burnet, 1-2 parts of borax and 4-6 parts of glycerol.
Preferably, the guaiac lotion is mainly prepared from the following raw materials in parts by weight:
15 parts of salvia miltiorrhiza, 15 parts of groundsel, 10 parts of astragalus, 10 parts of garden burnet, 2 parts of borax and 5 parts of glycerol.
The invention also provides a preparation process of the wound healing lotion, which comprises the following steps:
step one, taking prescribed amounts of salvia miltiorrhiza, groundsel, astragalus and garden burnet, cleaning and crushing;
step two, primary extraction, namely soaking the crushed four raw materials in water, decocting, and filtering to obtain primary filtrate and dregs;
step three, secondary extraction, namely adding the dregs of a decoction into water, decocting, and filtering to obtain secondary filtrate;
step four, concentration, mixing the primary filtrate and the secondary filtrate, concentrating and cooling;
step five, removing impurities, adding ethanol into the concentrated solution, uniformly stirring, refrigerating overnight, filtering, and recovering ethanol from the filtrate until no alcohol smell exists;
step six, preparing the liquid, adding water into borax, heating and stirring the mixture until the borax is dissolved, adding the mixture into the liquid medicine, stirring the mixture, standing the mixture overnight, filtering the mixture to obtain filtrate, adding glycerol and a proper amount of water into the filtrate, uniformly stirring the mixture, and sterilizing the mixture to obtain the wound healing lotion.
Preferably, in the second step, the four raw materials are added into water for soaking, wherein the amount of the water is 7-9 times of the weight of the raw materials, and the soaking time is 20-30min; the decoction time is 100-140min.
Preferably, in the third step, the decoction is carried out for 70-110min, wherein the dosage of water is 7-9 times of the weight of the decoction dregs.
Preferably, in the fourth step, the concentration is carried out until the weight ratio of the raw materials to the concentrated solution is 1 (1.4-1.6).
Preferably, in the fifth step, ethanol is added into the concentrated solution, and the amount of the ethanol is 2-3 times of the weight of the concentrated solution.
The invention also provides application of the wound healing lotion in preparation of wound cleaning and antibacterial drugs.
The invention finally provides an identification method of the guaiac lotion, which comprises the following steps:
identification of the salvia miltiorrhiza: shaking and extracting the wound healing lotion with diethyl ether, mixing the extractive solutions, evaporating to dryness, and dissolving the residue with methanol to obtain a test solution; performing thin layer chromatography, namely, spotting a sample on a silica gel G thin layer plate, developing by taking a mixture of toluene and ethyl acetate as a developing agent, airing, and observing;
and (3) identification of astragalus: extracting the wound healing lotion with diethyl ether under shaking, discarding diethyl ether, volatilizing water layer to remove diethyl ether, extracting with n-butanol under shaking, mixing extractive solutions, washing with potassium hydroxide solution and water to neutrality, evaporating n-butanol extractive solution to dryness, and dissolving residue with methanol to obtain sample solution; performing thin layer chromatography, spreading the sample on silica gel G thin layer plate, spreading with mixture of chloroform, methanol and water as developing agent, air drying, spraying with sulfuric acid ethanol solution, and oven drying until the spots are clear.
And (3) identifying the garden burnet root: evaporating the wound healing lotion to dryness, adding methanol solution of hydrochloric acid, heating and refluxing, cooling, filtering, extracting the filtrate with saturated diethyl ether, mixing the diethyl ether solutions, volatilizing, and dissolving with methanol to obtain sample solution; performing thin layer chromatography, spreading the sample on silica gel G thin layer plate, developing with mixture of toluene (saturated with water), ethyl acetate and formic acid as developing agent, air drying, spraying ferric trichloride ethanol solution, and observing.
Preferably, the method for identifying the components of the guaiac lotion comprises the following steps:
in the identification process of the salvia miltiorrhiza, the volume ratio of toluene to ethyl acetate in the mixture of toluene and ethyl acetate is 19;
in the identification process of the astragalus membranaceus, the volume ratio of trichloromethane to methanol to water in a mixture of the trichloromethane to the methanol to the water is 13;
in the identification process of the garden burnet, the volume ratio of toluene (saturated with water), ethyl acetate and formic acid in a mixture of toluene (saturated with water), ethyl acetate and formic acid is 6.
Preferably, the method for identifying the components of the guaiac lotion comprises the following steps:
in the identification process of the salvia miltiorrhiza, a control medicinal material solution of the salvia miltiorrhiza and a negative control solution without the salvia miltiorrhiza are prepared simultaneously; dropping the sample solution on the silica gel G thin layer plate, and dropping the reference medicinal solution of Saviae Miltiorrhizae radix and the negative reference solution containing no Saviae Miltiorrhizae radix on the silica gel G thin layer plate;
in the identification process of the astragalus, preparing an astragaloside IV reference substance solution and a negative reference solution without the astragalus simultaneously; spotting the sample on a silica gel G thin layer plate, and simultaneously spotting the astragaloside IV control solution and the negative control solution without radix astragali on the silica gel thin layer plate;
in the process of identifying the sanguisorba officinalis, preparing a gallic acid reference substance solution and a negative reference solution without the sanguisorba officinalis at the same time; while the test solution was spotted on the silica gel G thin layer plate, the gallic acid control solution and sanguisorba officinalis-free negative control solution were spotted on the silica gel G laminate plate.
According to the invention, borax is added in the formula in the prior art, has the effects of clearing heat and removing toxicity, reducing swelling and preventing corrosion, and has an antibacterial effect on common pyogenic bacteria such as staphylococcus aureus. Because the original formula contains more flavonoid and phenolic acid components, the solubility of the components is greatly improved under the alkaline condition, the pH value is increased after the borax is added, and the clarity of the solution is improved, so that the borax not only can obviously enhance the drug effect, but also can adjust the pH value to enhance the stability of the liquid medicine. In the formula, the groundsel herb is used as a monarch for clearing heat, removing toxicity and inhibiting bacteria, the salvia miltiorrhiza is used as a minister for activating blood and reducing swelling, the sanguisorba officinalis is used as an assistant for astringing and inducing astringency, the astragalus root is used for expelling toxin and expelling pus, borax is added for regulating the pH value, and the wound healing lotion formed by the five medicines can possibly integrate the action characteristics of the five medicinal materials, and can promote the discharge of pus of a wound surface which is difficult to heal, control inflammation, prevent infection and promote wound healing. In addition, glycerin is added into the liquid medicine to be used as a humectant and a softener.
Has the advantages that: compared with the prior art, the invention has the following advantages:
1. the wound healing lotion can improve the antibacterial effect, enhance the stability of the liquid medicine, promote the discharge of pus on the wound surface which is difficult to heal, control inflammation, prevent infection and promote wound healing, and has excellent effect.
2. According to the preparation process of the wound healing lotion, the wound healing lotion is prepared by steps of extracting, concentrating, removing impurities and the like of a traditional Chinese medicine prescription of the wound healing lotion, and the preparation method is simple in process and provides a theoretical basis for production and preparation of the wound healing lotion;
3. the component identification of the wound healing lotion provided by the invention utilizes the thin-layer chromatography to qualitatively identify and research the salvia miltiorrhiza, the astragalus membranaceus and the garden burnet in the wound healing lotion, can comprehensively reflect the information of chemical components contained in a traditional Chinese medicine compound, so as to preliminarily ensure the quality and curative effect of the product and provide a good solution for controlling the quality of the wound healing lotion.
Drawings
FIG. 1 is a process flow diagram of the preparation method of the present invention.
FIG. 2 is a schematic expanded view of Salvia miltiorrhiza in example 2 of the present invention;
FIG. 3 is an expanded view of Astragalus membranaceus in example 2 of the present invention;
FIG. 4 is a schematic development view of sanguisorba officinalis in example 2 of the present invention;
FIG. 5 is a graph showing the effect of borax on the pH stability of a wound healing lotion in Experimental example 3 of the present invention.
Detailed Description
The invention will be better understood from the following examples. However, those skilled in the art will readily appreciate that the description of the embodiments is only for illustrating the present invention and should not be taken as limiting the invention as detailed in the claims. The implementation conditions adopted in the embodiments can be further adjusted according to different requirements of specific use, and the implementation conditions not mentioned are conventional conditions in the industry. The technical features according to the respective embodiments of the present invention may be combined with each other as long as they do not conflict with each other.
Example 1
The wound healing lotion comprises the following components: saviae Miltiorrhizae radix, concha Haliotidis, radix astragali, radix Sangusorbae, borax, and glycerol;
the components and the contents (counted by weight parts) thereof are as follows: 15 parts of salvia miltiorrhiza, 15 parts of groundsel, 10 parts of astragalus, 10 parts of garden burnet, 2 parts of borax and 5 parts of glycerol.
The preparation method of the wound healing lotion comprises the following steps:
selecting materials, namely selecting high-quality raw materials, and taking salvia miltiorrhiza, groundsel, astragalus and garden burnet according to parts by weight;
pulverizing, namely pulverizing all the medicinal materials to similar granularity by using a pulverizing machine, wherein the garden burnet is coarsely pulverized and then pulverized, and cleaning and uniformly pulverizing the salvia miltiorrhiza, the groundsel, the astragalus and the garden burnet which are taken according to parts by weight;
step three, primary extraction, namely adding the four powdered raw materials into water with the weight of 8 times of that of the raw materials, soaking for 25min, then decocting for 120min, and filtering to obtain primary filtrate and dregs;
step four, secondary extraction, namely adding the dregs of a decoction into water with the weight 8 times that of the dregs of a decoction, decocting for 90min, and filtering to obtain secondary filtrate;
step five, concentration, mixing the primary filtrate and the secondary filtrate, performing high-temperature concentration in a water bath at 90 ℃, concentrating until the ratio of the medicinal materials to the concentrated solution is 1.5, and cooling;
removing impurities, namely adding 2.5 times of ethanol into the concentrated solution, uniformly stirring, refrigerating overnight, performing suction filtration, recovering the ethanol by using a rotary evaporator until no alcohol smell exists, and setting the water bath temperature to be 50 ℃;
and seventhly, preparing the liquid, adding a proper amount of water into borax, heating and stirring until the borax is dissolved, adding the borax into the liquid medicine, stirring, standing overnight, filtering to obtain a filtrate, adding glycerol and a proper amount of water into the filtrate, uniformly stirring, and sterilizing at 121 ℃ for 15min to obtain the wound healing lotion.
Example 2
This example provides a method for identifying the components of a wound healing lotion, specifically, a wound healing lotion prepared in example 1 was subjected to an identification test, which includes:
identification of the salvia miltiorrhiza: collecting 50ml of wound healing lotion, extracting with diethyl ether under shaking for 3 times (30, 20 ml), mixing extractive solutions, evaporating to dryness, and dissolving the residue with 1ml of methanol to obtain test solution. Pulverizing Saviae Miltiorrhizae radix reference material 1g, adding diethyl ether 50ml, and making into reference material solution by the same method as the test solution. Weighing the rest medicinal materials except the salvia miltiorrhiza according to the amount of 1 percent of the prescription amount, and preparing the medicinal materials into a negative control solution according to a preparation process and a preparation method of a test solution. According to the thin layer chromatography test, sucking 6ul of each of the three solutions, respectively dropping on the same silica gel G thin layer plate, developing by taking toluene-ethyl acetate (19).
And (3) identification of astragalus: collecting wound healing lotion 40ml, extracting with diethyl ether under shaking for 3 times (30, 20 ml), discarding diethyl ether, volatilizing diethyl ether in water layer, extracting with n-butanol under shaking for 3 times (30, 20 ml), mixing extractive solutions, washing with 1% potassium hydroxide solution for 3 times (20 ml each time), washing with water for 3 times to neutral (30 ml each time), evaporating n-butanol extractive solution to dryness, and dissolving the residue with 1ml methanol to obtain test solution. Adding methanol into astragaloside IV control to obtain 1mg solution per 1ml, and making into control solution. Weighing the rest medicinal materials except the astragalus according to the amount of 1 percent of the prescription amount, and preparing the negative control solution according to the preparation process and the preparation method of the test solution. According to the thin layer chromatography test, 6ul of each of the three solutions is sucked and respectively spotted on the same silica gel G thin layer plate, an upper layer solution of chloroform-methanol-water (13.
And (3) identifying the garden burnet root: taking 50ml of the guaiac lotion, evaporating to dryness, adding 50ml of a 50% methanol solution of 10% hydrochloric acid into the residue, heating and refluxing at 45 ℃ for 2 hours, cooling, and filtering. The filtrate was extracted with hydrochloric acid saturated ether for 2 times (25 ml ) with shaking, the ether solutions were combined, evaporated to dryness, and the residue was dissolved in 1ml of methanol to give a sample solution. Taking gallic acid control, adding methanol to obtain solution containing 0.5mg per 1ml, and making into control solution. Weighing the rest medicinal materials except sanguisorba officinalis according to the amount of 1 percent of the prescription amount, and preparing the negative control solution according to the preparation process and the preparation method of the test solution. According to the thin layer chromatography test, 6ul of each of the three solutions is sucked up and respectively spotted on the same silica gel G thin layer plate, and the three solutions are developed by taking toluene (saturated with water) -ethyl acetate-formic acid (6) as a developing solvent, taken out, dried and sprayed with a 1% ferric trichloride ethanol solution.
Performing component identification test on Saviae Miltiorrhizae radix, radix astragali and radix Sangusorbae according to the above method respectively, with the results shown in FIGS. 2-4; in FIGS. 2-4, 1-3 are the test solution, 4 is the control solution, and 5 is the negative control solution.
Specifically, fig. 2 shows a schematic diagram of thin-layer identification development of salvia miltiorrhiza at normal temperature, and it can be seen from the diagram that spots with the same color appear in the chromatogram of the test sample at the positions corresponding to the chromatograms of the reference drugs, and meanwhile, the negative control has no spots, which proves that other drugs in the prescription do not interfere with the identification of salvia miltiorrhiza.
FIG. 3 shows the schematic diagram of the thin-layer identification development of Astragalus membranaceus at normal temperature, and it can be seen from the diagram that spots of the same color appear in the chromatogram of the test solution at the position corresponding to the chromatogram of the reference solution, and meanwhile, the negative control has no spot, which proves that other medicinal materials in the prescription do not interfere with the identification of Astragalus membranaceus.
FIG. 4 shows the schematic diagram of the thin-layer identification development of sanguisorba officinalis at normal temperature, and it can be seen from the diagram that spots with the same color appear in the chromatogram of the test solution at the position corresponding to the chromatogram of the reference solution, and meanwhile, the negative control has no spots, which proves that other medicinal materials in the prescription have no interference on the identification of sanguisorba officinalis.
Comparative example 1
This comparative example is substantially the same as example 1 except that: no borax was added.
Experimental example 1
In vitro bacteriostatic test, the guaiac lotion prepared in example 1 and comparative example 1 of the present application and a 2% boric acid solution were treated to prepare an experimental group, and a physiological saline solution was used as a control group.
Preparation of a culture medium: (1) 1:1 concentration group: 0.95 g of MH agar powder 4 parts to a 100ml flask are weighed, and 25ml of comparative example 1, 2% borax and distilled water (a control group) are respectively added into each flask; (2) 1:5 concentration group: 0.95 g of MH agar powder 4 parts is weighed into a 100ml flask, 5ml of borax of comparative example 1, example 1 and 2% is respectively added, 20ml of distilled water is respectively added into each flask, and 25ml of distilled water is directly added into a control group. Autoclaving at 121 deg.C for 15min, cooling to 56 deg.C, and pouring into 9cm plates (25 ml each). After the agar was completely solidified, the growth inhibitory effects on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, enterococcus faecalis, and candida albicans were determined, respectively, and the results are shown in table 1.
The result shows that 2 percent of borax and the guaiac lotion have certain inhibition effect on staphylococcus aureus, escherichia coli, pseudomonas aeruginosa, enterococcus faecalis and candida albicans, and the guaiac lotion added with borax has better inhibition effect than the guaiac lotion without borax and has certain synergistic effect.
TABLE 1 results of in vitro bacteriostatic test of wound healing lotion
Remarking: the concentration of the bacterial liquid a is 0.5 McLee unit, the amount of the bacterial liquid b is 0.05 McLee unit (note: 1 McLee unit is 3X 10) 8 )
+: for bacterial growth, -: the bacteria did not grow.
Experimental example 2
In a mouse staphylococcus aureus infectious wound repair experiment, a wound of a mouse treated by the wound healing lotion prepared in the embodiment 1 and the comparative example 1 of the application is taken as an experimental group, a wound of a mouse treated by normal saline is taken as a negative control group, a mouse in a model group is not treated, the change of the wound area of each group of mice is recorded, and the experimental result is shown in table 2.
The result shows that the wound healing lotion can effectively reduce the area of the wound surface of a mouse infected by staphylococcus aureus or escherichia coli, remarkably improve the shrinkage rate of the wound surface, and has a promoting effect on the healing of the wound surface, wherein the wound healing lotion is characterized in that ulcer is reduced, granulation tissue at the bottom of the ulcer is proliferated and matured, and the regeneration of epithelium at the edge of the ulcer is increased. And the group of the embodiment 1 added with the borax is superior to the group of the comparative example 1 not added with the borax, and has statistical difference with the model group and the negative control group.
TABLE 2 Effect of wound healing lotion on wound healing in Staphylococcus aureus infected mice
Note: p <0.05, p <0.01; compared to negative controls, # p <0.05, # p <0.01.
Experimental example 3
Stability test, the stability of the product of example 1 and comparative example 1 was examined under the conditions close to the actual storage conditions of the product, and the pH was measured by sampling at 25. + -. 2 ℃ on days 1, 2, 4, 8, 16, 30 and 60, respectively, and the results are shown in FIG. 5.
The results show that as the number of days of storage increased, example 1 showed no sedimentation, substantially no change in pH, and long-term stability. However, in comparative example 1 in which no borax was added, the pH was significantly lowered after storage for about 10 days, and the precipitation phenomenon was observed with the naked eye.
The experimental results show that compared with the wound healing lotion prepared by the prescription added with borax, the wound healing lotion prepared by the invention enhances the stability of the lotion, enhances the bacteriostatic effect of the lotion and has better promotion effect on wound healing.
In summary, the preparation method provided by the application is simple to operate, and the activity of the effective ingredients can be ensured to the maximum extent in the preparation process. The cleaning agent can be used for cleaning the wound surface at the first time after injury to prevent bacterial root implantation and effectively promote the healing of the wound surface.
While there have been shown and described what are at present considered to be the preferred embodiments of the present invention, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention. All the components not specified in the present embodiment can be realized by the prior art.
Claims (10)
1. The wound healing lotion is characterized by being mainly prepared from the following raw materials in parts by weight:
13-19 parts of salvia miltiorrhiza, 13-19 parts of groundsel, 8-14 parts of astragalus, 8-14 parts of garden burnet, 1-2 parts of borax and 4-8 parts of glycerol.
2. The wound healing lotion according to claim 1, wherein the wound healing lotion is prepared from the following raw materials in parts by weight:
13-17 parts of salvia miltiorrhiza, 13-17 parts of groundsel, 8-12 parts of astragalus, 8-12 parts of garden burnet, 1-2 parts of borax and 4-6 parts of glycerol.
3. The wound healing lotion according to claim 1, wherein the wound healing lotion is mainly prepared from the following raw materials in parts by weight:
15 parts of salvia miltiorrhiza, 15 parts of groundsel, 10 parts of astragalus, 10 parts of garden burnet, 2 parts of borax and 5 parts of glycerol.
4. A process for the preparation of the guaiac lotion as defined in any one of claims 1 to 3 which comprises the steps of:
step one, taking the salvia miltiorrhiza, groundsel, astragalus and garden burnet according to the prescription amount, cleaning and crushing;
step two, primary extraction, namely soaking the crushed four raw materials in water, decocting, and filtering to obtain primary filtrate and dregs;
step three, secondary extraction, namely adding the dregs of a decoction into water, decocting, and filtering to obtain secondary filtrate;
step four, concentration, mixing the primary filtrate and the secondary filtrate, concentrating and cooling;
step five, removing impurities, adding ethanol into the concentrated solution, uniformly stirring, refrigerating overnight, filtering, and recovering ethanol from the filtrate until no alcohol smell exists;
step six, preparing the liquid, adding water into borax, heating and stirring the mixture until the borax is dissolved, adding the mixture into the liquid medicine, stirring the mixture, standing the mixture overnight, filtering the mixture to obtain filtrate, adding glycerol and a proper amount of water into the filtrate, uniformly stirring the mixture, and sterilizing the mixture to obtain the wound healing lotion.
5. The preparation process of the wound healing lotion according to claim 4, wherein in the second step, the four raw materials are added into water for soaking, wherein the amount of water is 7-9 times of the weight of the raw materials, and the soaking time is 20-30min; the decocting time is 100-140min.
6. The preparation process of the guaiac lotion as claimed in claim 4, wherein in step three, the decoction is carried out with water in an amount 7-9 times the weight of the herb residue for 70-110min.
7. The process for preparing a wound healing lotion according to claim 4, wherein in the fourth step, the concentration is carried out until the weight ratio of the raw material to the concentrated solution is 1 (1.4-1.6).
8. The process for preparing a wound healing lotion according to claim 4, wherein in the fifth step, ethanol is added to the concentrated solution in an amount of 2 to 3 times the weight of the concentrated solution.
9. Use of a wound healing lotion according to any one of claims 1 to 3 in the preparation of wound cleansing and antibacterial medicaments.
10. The method for identifying an wound healing lotion according to any one of claims 1 to 3, comprising the steps of:
identification of the salvia miltiorrhiza: extracting the wound healing lotion with diethyl ether under shaking, mixing extractive solutions, evaporating to dryness, and dissolving the residue with methanol to obtain sample solution; performing thin layer chromatography, namely, spotting a sample on a silica gel G thin layer plate, developing by taking a mixture of toluene and ethyl acetate as a developing agent, airing, and observing;
and (3) identification of astragalus: extracting the wound healing lotion with diethyl ether under shaking, discarding diethyl ether, volatilizing diethyl ether in water layer, extracting with n-butanol under shaking, mixing extractive solutions, washing with potassium hydroxide solution and water to neutrality, evaporating n-butanol extractive solution to dryness, and dissolving residue with methanol to obtain test solution; performing thin layer chromatography, spreading the sample on silica gel G thin layer plate, spreading with mixture of chloroform, methanol and water as developing agent, air drying, spraying with sulfuric acid ethanol solution, and oven drying until the spots are clear.
And (3) identifying the garden burnet root: evaporating the wound healing lotion to dryness, adding methanol solution of hydrochloric acid, heating and refluxing, cooling, filtering, extracting the filtrate with hydrochloric acid saturated diethyl ether under shaking, mixing the diethyl ether solution, evaporating to dryness, and dissolving with methanol to obtain sample solution; performing thin layer chromatography, spreading the sample on silica gel G thin layer plate, developing with mixture of toluene (saturated with water), ethyl acetate and formic acid as developing agent, air drying, spraying ferric trichloride ethanol solution, and observing.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211554965.6A CN115957258A (en) | 2022-12-06 | 2022-12-06 | Wound healing lotion and preparation process and application thereof |
| CN202311641870.2A CN117482140A (en) | 2022-12-06 | 2023-12-04 | Wound healing lotion and preparation process and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211554965.6A CN115957258A (en) | 2022-12-06 | 2022-12-06 | Wound healing lotion and preparation process and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115957258A true CN115957258A (en) | 2023-04-14 |
Family
ID=87351980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211554965.6A Withdrawn CN115957258A (en) | 2022-12-06 | 2022-12-06 | Wound healing lotion and preparation process and application thereof |
| CN202311641870.2A Pending CN117482140A (en) | 2022-12-06 | 2023-12-04 | Wound healing lotion and preparation process and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311641870.2A Pending CN117482140A (en) | 2022-12-06 | 2023-12-04 | Wound healing lotion and preparation process and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN115957258A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421008A (en) * | 2016-05-25 | 2017-02-22 | 中国人民解放军南京军区南京总医院 | Wound-healing traditional Chinese medicine composition for anal fistula as well as preparation method and application of traditional Chinese medicine |
| CN106421160A (en) * | 2016-05-25 | 2017-02-22 | 中国人民解放军南京军区南京总医院 | Wound-cleaning traditional Chinese medicine composition for anal fistula as well as preparation method and application of traditional Chinese medicine |
-
2022
- 2022-12-06 CN CN202211554965.6A patent/CN115957258A/en not_active Withdrawn
-
2023
- 2023-12-04 CN CN202311641870.2A patent/CN117482140A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106421008A (en) * | 2016-05-25 | 2017-02-22 | 中国人民解放军南京军区南京总医院 | Wound-healing traditional Chinese medicine composition for anal fistula as well as preparation method and application of traditional Chinese medicine |
| CN106421160A (en) * | 2016-05-25 | 2017-02-22 | 中国人民解放军南京军区南京总医院 | Wound-cleaning traditional Chinese medicine composition for anal fistula as well as preparation method and application of traditional Chinese medicine |
Non-Patent Citations (1)
| Title |
|---|
| 王燕玲: "肛瘘愈创洗液的研制及疗效的初步评价", no. 11, pages 057 - 6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117482140A (en) | 2024-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111744054B (en) | Antibacterial wound surface dressing capable of promoting healing and preparation method thereof | |
| CN112316017A (en) | Gynecological antibacterial gel and preparation method thereof | |
| US10478463B2 (en) | External-use medicament for cleaning and care of the ovaries, vagina, and vulva | |
| CN102793881A (en) | Traditional Chinese medicine gel for treating vaginitis as well as preparation method and application of traditional Chinese medicine gel | |
| CN109966434B (en) | Traditional Chinese medicine composition, traditional Chinese medicine compound preparation, and preparation method and application thereof | |
| CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
| CN105126145A (en) | Chinese herbal medicinal sterilizing and purifying material | |
| CN115957258A (en) | Wound healing lotion and preparation process and application thereof | |
| CN113952498B (en) | Chinese medicine multi-component liquid wound healing dressing and preparation method thereof | |
| CN108606994A (en) | A kind of liquid for cleaning private part and preparation method thereof | |
| CN108785363A (en) | Application of the yellow wingceltis platymiscium perfume (or spice) material in the drug for preparing treatment microorganism infection | |
| CN101264130B (en) | Film coating agent for treating skin ulcer | |
| CN111514119A (en) | Adhesive bandage containing industrial hemp root extract and preparation method thereof | |
| CN105126149A (en) | Composite chitosan application for medical use | |
| CN111228561A (en) | Smearing-free wound dressing containing traditional Chinese medicine matrix | |
| CN106511770B (en) | Traditional Chinese medicine preparation for treating herpes zoster and preparation method thereof | |
| CN111265639A (en) | Coptis healing ointment and clinical research method for treating burn by using gauze thereof | |
| CN104623443A (en) | Traditional Chinese medicine for treating skin erosion | |
| CN107375384A (en) | A kind of gynaecological gel containing P-Cymene and preparation method thereof | |
| CN1093406C (en) | Wound healing oil and its preparation | |
| CN110664934B (en) | Antibacterial and antipruritic traditional Chinese medicine composition and preparation method and application thereof | |
| CN115624592A (en) | Lotion for eliminating dampness and healing sores and preparation method thereof | |
| CN1156307C (en) | Vagina spry containing biological active factor | |
| CN101658583B (en) | Traditional Chinese medicine for treating cold-dampness type skin ulcer and preparation method thereof | |
| CN100393318C (en) | Asiaticoside external use sterile powder and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20230414 |